Alanna Temme, President of Midsized Biotech Alliance of America, released the following statement on the introduction of H.R. 7837, the Most Favored Patient Act of 2026, which threatens midsized biotech innovation and investment:
“America should be strengthening its innovation ecosystem, not weakening it.
“The American scientists, companies, and innovators are working to save lives right here on American soil, and our policies should allow them to keep doing what they do best.
“Any policy linked to price controls would reduce the resources available to reinvest in future research. That means fewer clinical trials, delayed treatments, and in some cases, therapies that never reach patients at all. That would be a loss, not just for the industry, but for every family waiting for answers.
“One-size-fits-all biotech policies that treat every biotech company the same will undermine America’s leading innovators. We are ready to work with policymakers to lower costs, protect patients, and secure the pipeline of innovation.”
H.R. 7837 would require the United States to tie the prices paid by Medicare and Medicaid for certain prescription drugs to international pricing benchmarks. Under the proposal, the U.S. price would be set at the second-lowest net price paid among eight reference countries: Canada, Denmark, France, Germany, Italy, Japan, Switzerland, and the United Kingdom, using a “Most Favored Nation” pricing system.
Representing the driving force of American biotechnology, innovative biopharmaceutical companies, MBAA members fuel U.S. jobs, research, and cures that define the future of life sciences. Collectively, MBAA member companies:
- Employ 12,300 Americans
- 5,000+ employees in R&D roles (about 41% of workforce)
- Invested $6.5 billion in R&D in 2024
- Generated $17 billion in global revenue in 2024
- Nearly 40% of revenue reinvested in R&D, far above the 15–20% typical of large pharmaceutical companies
- 32 medicines currently on the U.S. market
- 75 drug candidates in clinical development
- 22 FDA orphan drug designations targeting rare and difficult diseases